The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

The trailblazing study will use the data from up to 1.4million NHS patients to test whether its shingles vaccine reduces the ...

GSK has announced a partnership with the UK Dementia Research Institute and Health Data Research UK to explore a potential ...

To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Dr. Nisha Acharya got a letter from the National Institutes of Health terminating her grant to study the safety and ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...